Contribute Try STAT+ Today

It’s time to talk about biotech and 2021. What will the year ahead look like for biotech and pharma companies and for the investors who finance the drugs they develop?

Adam Koppel, a longtime health care investor and industry executive, joined STAT’s biotech podcast, “The Readout Loud” to try to answer that question. Four years ago, he co-founded Bain Capital Life Sciences, a Boston-based life sciences investment fund with more than $2 billion in assets under management.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.